Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Calquence approved in CLL in the US

November 21, 2019

Qtrilmet approved in the EU for treatment of T2D

November 15, 2019

FDA accepts regulatory submission for selumetinib

November 14, 2019

Anifrolumab demonstrated superiority in TULIP 2

November 12, 2019

Roxadustat pooled analyses: no increased CV risk

November 11, 2019

Roxadustat significantly increased haemoglobin

November 8, 2019

Calquence data to show improved progression-free

November 6, 2019

AstraZeneca divests rights to Seroquel and

October 30, 2019

Imfinzi and Imfinzi plus tremelimumab delayed

October 28, 2019

AstraZeneca year-to-date and Q3 2019 results

October 24, 2019

Farxiga approved in the US to reduce the risk of

October 21, 2019

Trastuzumab deruxtecan granted FDA Priority Review

October 17, 2019

Fasenra approved in the US for self-administration

October 4, 2019

AstraZeneca divests rights for Losec to Cheplaphar

October 1, 2019

Update on US regulatory review of PT010 in COPD

October 1, 2019

Lynparza more than doubled the time without

September 30, 2019

Tagrisso is the only 1st-line treatment for EGFR-

September 30, 2019

Lynparza improved the time women lived without

September 30, 2019

Qtrilmet recommended for approval in EU by CHMP

September 23, 2019

AstraZeneca amends collaboration with Ironwood

September 18, 2019

Imfinzi is first immunotherapy to show both

September 9, 2019

Tagrisso approved in China as a 1st-line treatment

September 4, 2019

Brilinta reduced the risk of cardiovascular events

September 2, 2019

Detailed results from Phase III DAPA-HF trial

September 2, 2019

Anifrolumab Phase III trial meets primary endpoint

August 29, 2019

Fasenra granted US Orphan Drug Designation for

August 28, 2019

Breztri Aerosphere Phase III ETHOS trial met

August 28, 2019

Roxadustat approved in China for the treatment of

August 22, 2019

AstraZeneca agrees to buy US FDA Priority Review

August 22, 2019

Update on the Phase III NEPTUNE trial

August 21, 2019

Farxiga met primary endpoint in landmark Phase III

August 20, 2019

Lynparza Phase III PAOLA-1 trial met primary endpo

August 14, 2019

Calquence granted US Breakthrough Therapy Designat

August 14, 2019

Amendment: Tagrisso significantly improves overall

August 9, 2019

Tagrisso significantly improves overall survival

August 9, 2019

Lynparza Phase III PROfound trial in HRR*

August 7, 2019

Forxiga label updated in the EU in type-2 diabetes

August 5, 2019

AZN: H1 2019 Results

July 25, 2019

Update on US regulatory decision for Farxiga

July 15, 2019

Imfinzi granted US Orphan Drug Designation for

July 12, 2019

Forxiga receives positive EU CHMP opinion for

July 1, 2019

Fasenra receives positive EU CHMP opinion for self

July 1, 2019

Imfinzi improves overall survival at interim

June 27, 2019

Lynparza approved in Japan for 1st-line

June 19, 2019

Breztri Aerosphere (PT010) approved in Japan for

June 19, 2019

Bevespi Aerosphere approved by the Japanese

June 19, 2019

Lynparza approved in the EU for 1st-line

June 18, 2019

Calquence significantly prolonged the time patient

June 17, 2019

Publication of a Prospectus

June 12, 2019

Calquence Phase III ELEVATE-TN trial met primary

June 6, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.